SCHEMBL70217

SCHEMBL70217

CCOC(=O)c1ccc(SSc2ccc(C(=O)OCC)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.66
CA2 P00918 3/20 0.66
CA12 O43570 2/20 0.66
CA7 P43166 2/20 0.66
CA9 Q16790 2/20 0.66
CA14 Q9ULX7 2/20 0.66
ESR1 P03372 1/20 0.66
ESR2 Q92731 1/20 0.66
LMNA P02545 2/20 0.63
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
MAOA P21397 1/20 0.63
HPGD P15428 4/20 0.56
HTT P42858 2/20 0.56
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
MAPT P10636 3/20 0.54
CASP3 P42574 1/20 0.54
TRPV1 Q8NER1 1/20 0.54
SENP7 Q9BQF6 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11173844 0.92 CA1 (0.61) CA1CA2CA12CA7CA9
SCHEMBL28510538 0.88 CA1 (0.66) CA1CA2CA12CA7CA9
SCHEMBL87450 0.87 CA1 (0.83) CA1CA2CA12CA7CA9
SCHEMBL147669 0.86 MEN1 (0.67) CA1CA2CA12CA7CA9
SCHEMBL27667917 0.85 CA1 (0.79) CA1CA2CA12CA7CA9
SCHEMBL30271267 0.85 CA1 (0.79) CA1CA2CA12CA7CA9
SCHEMBL7746905 0.85 CA1 (0.79) CA1CA2CA12CA7CA9
SCHEMBL21440358 0.85 CA1 (0.79) CA1CA2CA12CA7CA9
SCHEMBL27647572 0.85 CA1 (0.79) CA1CA2CA12CA7CA9
SCHEMBL27667926 0.85 CA1 (0.79) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987516-B2 Process for producing arylsulfur pentafluorides UBE INDUSTRIES, LTD. (JP) 2015-03-24 US disclosed
EP-2468722-B1 Process for producing arylsulfur halotetrafluorides UBE INDUSTRIES (JP) 2014-10-01 EP disclosed
EP-2468721-B1 Process for producing arylsulfur pentafluorides UBE INDUSTRIES (JP) 2014-02-26 EP disclosed
EP-2468720-B1 Process for producing arylsulfur pentafluorides UBE INDUSTRIES (JP) 2013-11-27 EP disclosed
EP-2468719-B1 Process for producing arylsulfur pentafluorides UBE INDUSTRIES (JP) 2013-10-16 EP disclosed
EP-2137144-B1 PROCESS FOR PRODUCING ARYLSULFUR PENTAFLUORIDES UBE INDUSTRIES (JP) 2013-07-31 EP disclosed
US-8399720-B2 Methods for producing fluorinated phenylsulfur pentafluorides UBE INDUSTRIES, LTD. (JP) 2013-03-19 US disclosed
EP-2479203-A1 AROMATIC POLYESTER Muroran Institute of Technology (JP) 2012-07-25 EP disclosed
US-20120172570-A1 AROMATIC POLYESTER NITTA CORPORATION 2012-07-05 US disclosed
EP-2468722-A1 Process for producing arylsulfur halotetrafluorides UBE Industries, Ltd. (JP) 2012-06-27 EP disclosed
US-7592491-B2 Process for producing arylsulfur pentafluorides IM&T RESEARCH, INC. (US) 2009-09-22 US disclosed
WO-2008118787-A1 PROCESS FOR PRODUCING ARYLSULFUR PENTAFLUORIDES IM & T RESEARCH, INC. (US) 2008-10-02 WO disclosed
US-20080234520-A1 PROCESS FOR PRODUCING ARYLSULFUR PENTAFLUORIDES IM&T RESEARCH, INC. (US) 2008-09-25 US disclosed
US-6114339-A TREATING PNEUMOCYSTIS AND TOXOPLASMOSIS DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) 2000-09-05 US disclosed
US-5866580-A TREATING AN ILLNESS CAUSED BY P. CARINII AND T. GONDII DUGUESNE UNIVERSITY OF THE HOLY GHOST (US) 1999-02-02 US disclosed
US-5736547-A RESISTS PNEUMOCYSTIS CARNII AND TOXOPLASMOSIS GONDII INFECTIONS IN IMMUNOCOMPROMISED PATIENTS; DIHYDROFOLATE REDUCTASE INHIBITORS; AIDS; ANTITUMOR AGENTS; SYNERGISTIC AGENT WITH SULFA DRUGS DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) 1998-04-07 US disclosed
US-5508281-A TREATING ILLNESS CAUSED BY PNEUMOCYSTIS CARINII OR TOXOPLASMOSIS GONDII DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) 1996-04-16 US disclosed
EP-0409382-A1 Glutamic acid derivatives THE WELLCOME FOUNDATION LIMITED (GB) 1991-01-23 EP disclosed
WO-1990014340-A1 GLUTAMIC ACID DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1990-11-29 WO disclosed
US-4921836-A ANTITUMOR AGENTS BURROUGHS WELLCOME CO. (US) 1990-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234520-A1 PROCESS FOR PRODUCING ARYLSULFUR PENTAFLUORIDES PFAS, MPST, ARSA CA1 2632/4885CA2 3338/4885CA12 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.